151 related articles for article (PubMed ID: 36170166)
41. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
42. Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib.
Brugioni E; Cathcart-Rake E; Metsker J; Gustafson E; Douglass L; Pluard TJ
Clin Breast Cancer; 2023 Jul; 23(5):469-477. PubMed ID: 37246120
[TBL] [Abstract][Full Text] [Related]
43. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
[TBL] [Abstract][Full Text] [Related]
44. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
[TBL] [Abstract][Full Text] [Related]
45. Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.
Comeaux JG; Culver JO; Lee JE; Dondanville D; McArthur HL; Quinn E; Gorman N; Ricker C; Li M; Lerman C
Mol Genet Genomic Med; 2022 Oct; 10(10):e2031. PubMed ID: 36054727
[TBL] [Abstract][Full Text] [Related]
46. [Hereditary breast and ovarian cancers].
Gevensleben H; Serçe N; Büttner R
Pathologe; 2010 Oct; 31(6):438-44. PubMed ID: 20848107
[TBL] [Abstract][Full Text] [Related]
47. Germline Testing and Somatic Tumor Testing for
Kwon JS; Tinker AV; Santos J; Compton K; Sun S; Schrader KA; Karsan A
JCO Precis Oncol; 2022 Oct; 6():e2200033. PubMed ID: 36265114
[TBL] [Abstract][Full Text] [Related]
48. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
49. The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.
Afghahi A; Kurian AW
Curr Treat Options Oncol; 2017 May; 18(5):27. PubMed ID: 28439798
[TBL] [Abstract][Full Text] [Related]
50. [Hereditary breast carcinomas pathologist's perspective].
Vincent-Salomon A; Bataillon G; Djerroudi L
Ann Pathol; 2020 Apr; 40(2):78-84. PubMed ID: 32241645
[TBL] [Abstract][Full Text] [Related]
51. Surgical Management of Inherited Breast Cancer: Role of Breast-Conserving Surgery.
Magnoni F; Sacchini V; Veronesi P; Bianchi B; Bottazzoli E; Tagliaferri V; Mazzotta E; Castelnovo G; Deguidi G; Rossi EMC; Corso G
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805017
[TBL] [Abstract][Full Text] [Related]
52. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
53. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
Saito A; Tanioka M; Hirata M; Watanabe T; Odaka Y; Shimoi T; Sudo K; Noguchi E; Ishikawa M; Yonemori K
Cancer Treat Res Commun; 2022; 32():100587. PubMed ID: 35696850
[TBL] [Abstract][Full Text] [Related]
54. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
[TBL] [Abstract][Full Text] [Related]
55. Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer Risk.
Vaidyanathan A; Kaklamani V
Curr Treat Options Oncol; 2021 Aug; 22(10):85. PubMed ID: 34424438
[TBL] [Abstract][Full Text] [Related]
56. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
[TBL] [Abstract][Full Text] [Related]
57. Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.
Yang X; Wu J; Lu J; Liu G; Di G; Chen C; Hou Y; Sun M; Yang W; Xu X; Zhao Y; Hu X; Li D; Cao Z; Zhou X; Huang X; Liu Z; Chen H; Gu Y; Chi Y; Yan X; Han Q; Shen Z; Shao Z; Hu Z
PLoS One; 2015; 10(4):e0125571. PubMed ID: 25927356
[TBL] [Abstract][Full Text] [Related]
58. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
[TBL] [Abstract][Full Text] [Related]
59. [Breast cancer susceptibility genes].
Díez O; Gutiérrez-Enríquez S; Ramón y Cajal T
Med Clin (Barc); 2006 Mar; 126(8):304-10. PubMed ID: 16527158
[TBL] [Abstract][Full Text] [Related]
60. [Chinese expert consensus on drug interaction management of poly ADP-ribose polymerase inhibitors].
; ; ; ;
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):584-593. PubMed ID: 37337129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
